# A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

> **NCT05388903** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 64 (actual)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** DS-2325a
- **DRUG:** DS-2325a
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05388903
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-20
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-01-26
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388903, "A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05388903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*